MA41730B1 - Utilisation de dérivé de benzimidazole pour l'acidité nocturne - Google Patents

Utilisation de dérivé de benzimidazole pour l'acidité nocturne

Info

Publication number
MA41730B1
MA41730B1 MA41730A MA41730A MA41730B1 MA 41730 B1 MA41730 B1 MA 41730B1 MA 41730 A MA41730 A MA 41730A MA 41730 A MA41730 A MA 41730A MA 41730 B1 MA41730 B1 MA 41730B1
Authority
MA
Morocco
Prior art keywords
acidity
benzimidazole derivative
night
present application
derivative compound
Prior art date
Application number
MA41730A
Other languages
English (en)
Other versions
MA41730A1 (fr
Inventor
Ha Jin Lee
Bong Tae Kim
Hyun Kim
Ji Yeon Nam
Jie Eun Park
Geun Seog Song
Shin Young Ryu
Shinichi Koizumi
Nobuyuki Takahashi
Masaomi Tajimi
Original Assignee
Cj Healthcare Corp
Raqualia Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57504150&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA41730(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cj Healthcare Corp, Raqualia Pharma Inc filed Critical Cj Healthcare Corp
Publication of MA41730A1 publication Critical patent/MA41730A1/fr
Publication of MA41730B1 publication Critical patent/MA41730B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)

Abstract

La présente demande concerne des utilisations d'un composé dérivé de benzimidazole pour remédier à et traiter l'acidité nocturne (nab). Le composé dérivé de benzimidazole selon la présente application permet de prévenir ou de traiter plus efficacement des troubles liés à l'acidité gastrique en améliorant et en traitant efficacement les symptômes d'acidité nocturne.
MA41730A 2015-06-08 2016-06-08 Utilisation de dérivé de benzimidazole pour l'acidité nocturne MA41730B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562172680P 2015-06-08 2015-06-08
PCT/KR2016/006072 WO2016200148A1 (fr) 2015-06-08 2016-06-08 Utilisation de dérivé de benzimidazole pour l'acidité nocturne

Publications (2)

Publication Number Publication Date
MA41730A1 MA41730A1 (fr) 2018-08-31
MA41730B1 true MA41730B1 (fr) 2019-03-29

Family

ID=57504150

Family Applications (1)

Application Number Title Priority Date Filing Date
MA41730A MA41730B1 (fr) 2015-06-08 2016-06-08 Utilisation de dérivé de benzimidazole pour l'acidité nocturne

Country Status (27)

Country Link
US (2) US10512635B2 (fr)
EP (1) EP3305291B1 (fr)
JP (1) JP6792269B2 (fr)
KR (3) KR20160144927A (fr)
CN (2) CN118557572A (fr)
CL (1) CL2017003133A1 (fr)
CY (1) CY1124590T1 (fr)
DK (1) DK3305291T3 (fr)
ES (1) ES2890481T3 (fr)
HK (1) HK1252562A1 (fr)
HR (1) HRP20211046T1 (fr)
HU (1) HUE056322T2 (fr)
IL (1) IL256127B (fr)
LT (1) LT3305291T (fr)
MA (1) MA41730B1 (fr)
MX (1) MX374972B (fr)
MY (1) MY197209A (fr)
PH (1) PH12017502221A1 (fr)
PL (1) PL3305291T3 (fr)
PT (1) PT3305291T (fr)
RS (1) RS62074B1 (fr)
RU (1) RU2672248C1 (fr)
SG (1) SG11201710006PA (fr)
SI (1) SI3305291T1 (fr)
SM (1) SMT202100399T1 (fr)
TN (1) TN2017000510A1 (fr)
WO (1) WO2016200148A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101960357B1 (ko) * 2016-12-26 2019-03-20 씨제이헬스케어 주식회사 벤즈이미다졸 유도체를 포함하는 신규한 제제
KR102262743B1 (ko) * 2017-07-07 2021-06-09 에이치케이이노엔 주식회사 주사용 조성물
MX2021002278A (es) * 2018-08-29 2021-08-11 Hk Inno N Corp Composición para erradicar helicobacter pylori.
PL3927340T3 (pl) * 2019-02-18 2026-03-09 Hk Inno.N Corporation Kompozycja farmaceutyczna zawierająca tegoprazan do zapobiegania nawrotowi choroby refluksowej przełyku
UY39094A (es) * 2020-02-27 2021-07-30 Hk Inno N Corp Composición farmacéutica que comprende compuesto derivado de bencimidazol
WO2021251565A1 (fr) 2020-06-12 2021-12-16 Hk Inno.N Corporation Composition pharmaceutique comprenant un composé dérivé de benzimidazole
US10991190B1 (en) 2020-07-20 2021-04-27 Abbott Laboratories Digital pass verification systems and methods
AR123872A1 (es) * 2020-10-23 2023-01-18 Hk Inno N Corp Comprimido de desintegración oral, procedimiento de preparación del mismo, procedimiento para prevenir o tratar enfermedades y uso del mismo
WO2023106841A1 (fr) * 2021-12-08 2023-06-15 (주) 팜젠사이언스 Composé dérivé de benzimidazole et ses utilisations

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR043063A1 (es) * 2002-12-13 2005-07-13 Altana Pharma Ag Bencimidazoles 6-sustituidos y su uso como inhibidores de secreciones gastricas
US20050232992A1 (en) * 2003-09-03 2005-10-20 Agi Therapeutics Limited Proton pump inhibitor formulations, and methods of preparing and using such formulations
JP2008543824A (ja) * 2005-06-14 2008-12-04 ファイザー株式会社 アシッドポンプアンタゴニストとしてのクロマン置換ベンゾイミダゾール誘導体
WO2007072146A1 (fr) 2005-12-19 2007-06-28 Pfizer Japan Inc. Benzimidazoles substitues par des chromanes et leur utilisation en tant qu’inhibiteurs de la pompe a protons
CA2665226C (fr) 2006-10-05 2014-05-13 Santarus, Inc. Nouvelles formulations pour une liberation immediate d'inhibiteurs de pompe a protons et procedes d'utilisation de ces formulations
WO2008151927A2 (fr) 2007-06-15 2008-12-18 Nycomed Gmbh Dérivés de benzimidazole à substitution 6-n pharmaceutiquement actifs
LT2262790T (lt) 2008-03-10 2017-08-25 Takeda Pharmaceutical Company Limited Benzimidazolo junginio kristalas
EP2452680B1 (fr) * 2009-07-09 2019-12-18 RaQualia Pharma Inc. Antagoniste de la pompe à acide destiné au traitement de maladies associées à un transit gastro-intestinal anormal
CN102140099A (zh) 2010-02-02 2011-08-03 山东轩竹医药科技有限公司 新的吡啶衍生物
RU2537140C1 (ru) * 2013-09-17 2014-12-27 Леонид Федосеевич Ляпустин Способ антихеликобактерной терапии желудка и двенадцатиперстной кишки

Also Published As

Publication number Publication date
HK1252562A1 (zh) 2019-05-31
HUE056322T2 (hu) 2022-02-28
TN2017000510A1 (en) 2019-04-12
CN108012527A (zh) 2018-05-08
WO2016200148A1 (fr) 2016-12-15
IL256127A (en) 2018-02-28
CN118557572A (zh) 2024-08-30
LT3305291T (lt) 2021-08-25
CL2017003133A1 (es) 2018-04-13
CY1124590T1 (el) 2022-07-22
US20180338954A1 (en) 2018-11-29
PH12017502221A1 (en) 2018-06-04
IL256127B (en) 2021-04-29
MY197209A (en) 2023-06-01
EP3305291A4 (fr) 2019-01-23
HRP20211046T1 (hr) 2021-10-01
US20200069652A1 (en) 2020-03-05
KR20180036931A (ko) 2018-04-10
RU2672248C1 (ru) 2018-11-13
DK3305291T3 (da) 2021-06-28
JP6792269B2 (ja) 2020-11-25
KR20200002739A (ko) 2020-01-08
PL3305291T3 (pl) 2021-11-02
SMT202100399T1 (it) 2021-09-14
MX374972B (es) 2025-03-06
KR102061052B1 (ko) 2019-12-31
RS62074B1 (sr) 2021-07-30
ES2890481T3 (es) 2022-01-20
US11033532B2 (en) 2021-06-15
EP3305291B1 (fr) 2021-05-19
SG11201710006PA (en) 2018-01-30
PT3305291T (pt) 2021-07-05
KR20160144927A (ko) 2016-12-19
MX2017015926A (es) 2018-07-06
JP2018516951A (ja) 2018-06-28
US10512635B2 (en) 2019-12-24
MA41730A1 (fr) 2018-08-31
SI3305291T1 (sl) 2021-08-31
EP3305291A1 (fr) 2018-04-11

Similar Documents

Publication Publication Date Title
MA41730A1 (fr) Utilisation de dérivé de benzimidazole pour l'acidité nocturne
ZA202409975B (en) Methods of treating schizophrenia
MA43518A (fr) 3-azabicyclo[3.1.0]hexanes substitués servant d'inhibiteurs de cétohexokinase
EA202090749A1 (ru) Способы совместной терапии для иммуномодуляции
MX2018010192A (es) Inhibidores de glucosidasa.
JO3653B1 (ar) ترايازول عوامل مساعدة لمستقبل apj
MX381417B (es) Inhibidores de glucosidasa.
MY196186A (en) Amino-Fluoropiperidine Derivatitves as Kinase Inhibitor
SA520412335B1 (ar) مشتقات أوكسي فلورو ببريدين كمثبط كيناز
EP2595482A4 (fr) Inhibiteurs de l'aldostérone synthase
EA201690007A1 (ru) Соединения, ингибирующие металлоферменты
MX2019010085A (es) Inhibidores de la glicosidasa de sulfoximina.
MX2025003294A (es) Moduladores de la expresion de apol1
MX387658B (es) Métodos para tratar y/o prevenir queratosis actínica.
MA49373B1 (fr) Compositions comprenant des souches bactériennes
MA38369A1 (fr) Peptides et compositions pour le traitement d'une lesion de l'articulation
EP3801232A4 (fr) Systèmes, procédés et dispositifs pour traiter des bradyarythmies, des tachyarythmies et de l'insuffisance cardiaque
EP3978025A4 (fr) Composition pour la prévention, l'amélioration ou le traitement de la gastrite ou de l'ulcère gastroduodénal comprenant un complexe polysaccharide chargé négativement-anthocyanine en tant que principe actif
MA39837B1 (fr) Quinazoline-thf-amines halogénées en tant qu'inhibiteurs de la pde1
EP3459541A4 (fr) Utilisation d'un composé carbamate pour le traitement préventif de maux de tête
MA43231B1 (fr) Bloqueur des canaux sodiques
WO2017042577A8 (fr) Nouvelle thérapie
EP3556366A4 (fr) Utilisation de composés de carbamate pour la prévention, l'atténuation ou le traitement d'un trouble bipolaire
EP3854392A4 (fr) Utilisation d'un composé carbamate pour la prévention, l'atténuation ou le traitement de crises épileptiques concomitantes
MX2015012164A (es) Métodos de tratamiento de enfermedad renal y otros trastornos.